The rapid and reversible activation of a calcium-independent plasmalogen-selective phospholipase A2 during myocardial ischemia.
Recent studies have demonstrated the existence of two members of a novel family of calcium-independent plasmalogen-selective phospholipases A2 in mammalian myocardium (Wolf, R. A., and R. W. Gross. 1985. J. Biol. Chem. 260:7295-7303; and Hazen, S. L., D. A. Ford, and R. W. Gross. 1991. J. Biol. Chem. 266:5629-5633). To examine the potential role of these calcium-independent phospholipases A2 in mediating membrane dysfunction during early myocardial ischemia, the temporal course of alterations in phospholipase A2 activity during global ischemia in Langendorf perfused rabbit hearts was quantified and compared with traditionally accepted markers of myocytic ischemic injury and anaerobic metabolism. We now report that membrane-associated calcium-independent plasmalogen-selective phospholipase A2 activity increased over 400% during 2 min of global ischemia (P less than 0.01), was near maximally activated (greater than 10-fold) after only 5 min of ischemia, and remained activated throughout the entire ischemic interval examined (2-60 min). Activation of membrane-associated plasmalogen-selective phospholipase A2 after 5 min of myocardial ischemia was rapidly reversible during reperfusion of ischemic tissue. Both the activation of phospholipase A2 and its reversibility during reperfusion were temporally correlated to alterations in myocytic anaerobic metabolism. Furthermore, activation of membrane-associated phospholipase A2 was essentially complete before electron microscopic evidence of cellular damage. Collectively, these results identify dynamic alterations in calcium-independent plasmalogen-selective phospholipase A2 activity during myocardial ischemia which precede irreversible cellular injury and demonstrate that activation of plasmalogen-selective phospholipase A2 is amongst the earliest biochemical alterations in ischemic myocardium.
Ford
D A
DA
Departments of *Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.
Hazen
S L
SL
Saffitz
J E
JE
Gross
R W
RW
D000818:Animals; D002118:Calcium / Q000494:pharmacology*; D003327:Coronary Disease / Q000201:enzymology*; D004789:Enzyme Activation; D008861:Microsomes / Q000201:enzymology; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D010741:Phospholipases A / Q000032:analysis*; D054467:Phospholipases A2; D010955:Plasmalogens / Q000494:pharmacology*; D011817:Rabbits
D010955:Plasmalogens; D010741:Phospholipases A; D054467:Phospholipases A2; D002118:Calcium